Powerful you
Developing solutions to harness your body's natural protective responses for the prevention and treatment of disease.
Powerful you
Developing solutions to harness your body's natural protective responses for the prevention and treatment of disease.
Learn about Protearin™
Exciting new research into solutions for dry eye disease and corneal disorders
Millions of Americans suffer from dry eye disease, yet there is currently only a single FDA-approved drug to treat the disorder and this drug is useful only for certain forms of dry eye.
Protearin™ is based on the glycoprotein clusterin, a natural, protective component of fluid-tissue interfaces throughout the body. Protearin™ targets the final common end point for all forms of dry eye, i.e., damage at the ocular surface and disruption of the ocular surface barrier.
PROMISING RESULTS
Preclinical testing and results of Protearin™ make a strong case to use clusterin as a biological drug to prevent or treat not only dry eye but also other corneal disorders involving damage to the ocular surface barrier.
Studies conducted at the University of Southern California in a preclinical model of dry eye demonstrated the remarkable potential for Protearin™ to protect the ocular surface barrier and to improve preexisting barrier disruption - potentially positioning Protearin™ as a first of its kind platform therapy for multiple conditions.
No drugs are currently on the market to address ocular surface barrier disruption.
Our Research
A potential application for the prevention and treatment of corneal disorders
Partnership
Born out of the Keck School of Medicine at USC
USC Institute for Genetic Medicine
Partnership
Born out of the Keck School of Medicine at USC
USC Institute for Genetic Medicine